Search
Close this search box.

Pharmacologic and Surgical Treatment for Disorders of the Stomach

Presented by Michael Camilleri, MD

Disorders of the stomach - Michael Camilleri
Dr. Michael Camilleri
Presentation Overview

This is a review of the current evidence of the effectiveness of drugs (unapproved by the Food and Drug Administration), potentially used for the treatment of gastroparesis and dyspepsia. The surgical approaches reviewed in this abstract, are endoscopic gastric per-oral endoscopic myotomy (G-POEM) and sleeve gastrectomy for gastroparesis. 

Approaches for Gastroparesis: Objectives 

  • Candidate Drugs for Gastroparesis
    • The selective NK1 receptor antagonists, tradipitant and aprepitant
    • Ghrelin receptor agonist: Relamorelin
    • 5-HT4 receptor agonists: Felcisetrag
  • Medications for Dyspepsia Associated with ↓ Gastric Accommodation
    • NK1 antagonists
    • Dopamine receptor antagonist: trazpiroben
  • Surgical and Procedural Approaches for Gastroparesis
    • G-POEM
    • Laparoscopic sleeve gastrectomy
About Dr. Camilleri

Michael Camilleri is a consultant in the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, Minnesota, and is Professor of Medicine, Pharmacology, and Physiology at Mayo Clinic College of Medicine and Science. His research interests include clinical enteric neurosciences, gut neurohormonal control, obesity, irritable bowel syndrome (IBS), and pharmacology and pharmacogenomics; his work is funded by National Institutes of Health.

He has received numerous awards and honors, including the 2012 Ismar Boas Medal from the German Society of Digestive and Metabolic Disease, the 2012 American Gastroenterological Association (AGA) Distinguished Mentor Award, the Janssen Research Award, the AGA Joseph B. Kirsner Award, the AGA Julius Friedenwald Medal in 2021, as well as honorary doctorates from the University of Antwerp (Belgium) and the University of Malta, and he was elected to the membership of the prestigious Association of American Physicians. Dr. Camilleri participates in educational and mentorship activities at Mayo Clinic and has mentored more than 80 national and international postdoctoral fellows and scientists. He maintains an active clinical practice in gastroenterology at Mayo Clinic, specializing in gastrointestinal motility disorders, gastroparesis, and functional GI disorders. He is past-president of the American Neurogastroenterology and Motility Society and the American Gastroenterological Association, former editor of Clinical Gastroenterology and Hepatology and Neurogastroenterology and Motility, and is currently an associate editor of American Journal of Physiology

Share this page
Topics of this article
Was this article helpful?

IFFGD is a nonprofit education and research organization. Our mission is to inform, assist, and support people affected by gastrointestinal disorders.

Our original content is authored specifically for IFFGD readers, in response to your questions and concerns.

If you found this article helpful, please consider supporting IFFGD with a small tax-deductible donation.

Related Information
2025 Travel Awards

Now Accepting Applications The International Foundation for Gastrointestinal Disorders (IFFGD) is pleased to announce that we are seeking applications/nominations for our 2025 Junior Academician Travel

Read More »
2025 Preceptorship Award

Now Accepting Applications The International Foundation for Gastrointestinal Disorders (IFFGD) is seeking applications for the 2025 Junior Faulty Preceptorship Award. The mission of IFFGD is

Read More »
Personal Stories
2025 Travel Awards

Now Accepting Applications The International Foundation for Gastrointestinal Disorders (IFFGD) is pleased to announce that we are seeking applications/nominations for our 2025 Junior Academician Travel

Read More »
2025 Preceptorship Award

Now Accepting Applications The International Foundation for Gastrointestinal Disorders (IFFGD) is seeking applications for the 2025 Junior Faulty Preceptorship Award. The mission of IFFGD is

Read More »
Skip to content